BioRestorative Therapies Secures Australian Patent Allowance For 3D Brown Adipose-Derived Stem Cell Aggregates

• GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. 
   
• BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages.

MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 2020265664 titled, "Non-naturally occurring three-dimensional (3D) brown adipose-derived stem cell aggregates, and methods of generating and using the same."

The newly allowed patent application provides the broadest protection obtained for BioRestorative's allogeneic, off-the-shelf, brown adipose-derived stem cell (BADSC) ThermoStem® technology, designed to treat obesity and metabolic disorders. The claims covered are: a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate.

With this allowance, BioRestorative is further protected in its development of potential next-generation, cell-based alternatives to GLP-1 drugs, which continue to be one of the fastest-growing therapeutic categories in the world.